Figure 1.
![Clinical events in extended thromboprophylaxis trials investigating both symptomatic and asymptomatic VTE. ADOPT, Apixaban Dosing to Optimize Protection from Thrombosis; APEX, The Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban; EXCLAIM, Extended Prophylaxis for Venous Thromboembolism in Acutely Ill Medical Patients with Prolonged Immobilization trial; MAGELLAN, Venous Thromboembolic Event [VTE] Prophylaxis in Medically Ill Patients.](https://ash.silverchair-cdn.com/ash/content_public/journal/hematology/2019/1/10.1182_hematology.2019000026/5/hem2019000026cf1.png?Expires=1722169004&Signature=hI7ny~ZZTsxwGqdlzVylsOcmf3btqDR03-3Lxx1mSGpS4R8oCa6aa4N4IMBevwcNY5yisc7HQkwtVjMkTkXORWeIXuWN43iToSQUkVQm67pL6Zaxgb~rMm6a~FVs7iDkDnLQ1JYwGy6TushCpmXrZFY-NJA~y925iq9QKFbPU35LgCGejy2e7XRK3lyb304LWTZyCrYJ0b-5j2CICpE5FxASN8yQdcHklQJxjFg-z-0Eab5ufsK-ZLyiI46lm4-SFt7Dr6-fJLNPhp2tS7KBFNuUVeVtwsdfN0CYA7KB9HwhWRUU59S5Cq920qrY-HDEAUu8Im0C6i1sgp6KKXTrVA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Clinical events in extended thromboprophylaxis trials investigating both symptomatic and asymptomatic VTE. ADOPT, Apixaban Dosing to Optimize Protection from Thrombosis; APEX, The Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban; EXCLAIM, Extended Prophylaxis for Venous Thromboembolism in Acutely Ill Medical Patients with Prolonged Immobilization trial; MAGELLAN, Venous Thromboembolic Event [VTE] Prophylaxis in Medically Ill Patients.